Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856717 | 0.91 | NPSR1 (0.46) | POLBSMN1; SMN2LMNANPSR1KMT2A | |
| SCHEMBL2863274 | 0.88 | ALDH1A1 (0.41) | POLBNPSR1KMT2AMEN1NPC1 | |
| SCHEMBL2856685 | 0.87 | NPSR1 (0.49) | NPSR1KMT2AMEN1TSHRKCNN4 | |
| SCHEMBL2870723 | 0.82 | MEN1 (0.39) | NPSR1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2864826 | 0.82 | F10 (0.40) | POLBLMNANPSR1RAB9A | |
| SCHEMBL2860452 | 0.82 | GRIN2B (0.43) | SMN1; SMN2NPSR1NPC1RAB9A | |
| SCHEMBL2862239 | 0.81 | HTT (0.39) | POLBSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL6039852 | 0.81 | NPSR1 (0.36) | POLBSMN1; SMN2NPSR1KMT2AMEN1 | |
| SCHEMBL2866314 | 0.81 | KMT2A (0.46) | POLBSMN1; SMN2LMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL2861673 | 0.81 | NPSR1 (0.35) | POLBSMN1; SMN2NPSR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | POLB 3625/4885SMN1; SMN2 4533/4885LMNA 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.